How Catalyst Biosciences partnered with Mosaic to develop a long-acting C3 inactivator for GA and dAMD

Ingenia Therapeutics tops current standard of care for degenerative retinal disease with modified bispecific antibody technology

Solving Drug Discovery Challenges: Optimizing a targeted bispecific antibody to improve expression and binding